Startseite>>Signaling Pathways>> Neuroscience>> Parkinson>>PF 9601N

PF 9601N

Katalog-Nr.GC49201

An inhibitor of MAO-B

Products are for research use only. Not for human use. We do not sell to patients.

PF 9601N Chemische Struktur

Cas No.: 133845-63-3

Größe Preis Lagerbestand Menge
5 mg
75,00 $
Auf Lager
10 mg
135,00 $
Auf Lager
25 mg
278,00 $
Auf Lager
50 mg
445,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PF 9601N is an inhibitor of monoamine oxidase B (MAO-B).1 It selectively inhibits MAO-B in mouse brain homogenates ex vivo (ID50 = 381 nmol/kg) and prevents MPTP-induced reductions in dopamine levels in the striatum of 8- to 9-week-old mice when administered at doses ranging from 29.5 to 8.47 µmol/kg. PF 9601N (0.027 µmol/kg) prevents MPTP-induced lesions in 9- to 10-month-old mice. It also increases the duration of contralateral rotational behavior induced by L-DOPA in a rat model of Parkinson’s disease induced by 6-OHDA when administered at doses of 40 and 60 mg/kg.2

1.Perez, V., and Unzeta, M.PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 miceNeurochem. Int.42(3)221-229(2003) 2.Prat, G., PÉrez, V., Rubi, A., et al.The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned ratsJ. Neural Transm. (Vienna)107(4)409-417(2000)

Bewertungen

Review for PF 9601N

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF 9601N

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.